Eucrates Biomedical Acquisition Overview
Eucrates Biomedical Acquisition (EUCR) has a P/E ratio of 5.4, below the sector sector average of 44.85.
Get informed when a big investor buys or sells
+ Follow5.40
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
As of the most recent data, EUCR shows a P/E ratio of 5.4. That is below the sector sector average of 44.85. Scroll down for historical charts and peer comparison views.
The its sector sector average P/E ratio is about 44.85. Eucrates Biomedical Acquisition is at 5.4, which is lower that average. That is roughly 88.0% below the sector mean. Use the comparison chart on this page to see how EUCR stacks up against individual peers as well.
Investors watch EUCR's P/E ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. Eucrates Biomedical Acquisition's latest reading is 5.4. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.
Besides this p/e ratio page, Stockcircle has Eucrates Biomedical Acquisition's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect P/E ratio (currently 5.4) with ownership activity and broader fundamentals.
